Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

310 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial.
Otvos JD, Guyton JR, Connelly MA, Akapame S, Bittner V, Kopecky SL, Lacy M, Marcovina SM, Muhlestein JB, Boden WE. Otvos JD, et al. Among authors: muhlestein jb. J Clin Lipidol. 2018 Mar-Apr;12(2):348-355.e2. doi: 10.1016/j.jacl.2018.01.002. Epub 2018 Jan 12. J Clin Lipidol. 2018. PMID: 29409728 Free PMC article. Clinical Trial.
Comparison of effects of high (80 mg) versus low (20 mg) dose of simvastatin on C-reactive protein and lipoproteins in patients with angiographic evidence of coronary arterial narrowing.
Meredith KG, Horne BD, Pearson RR, Maycock CA, Lappe DL, Anderson JL, Muhlestein JB. Meredith KG, et al. Among authors: muhlestein jb. Am J Cardiol. 2007 Jan 15;99(2):149-53. doi: 10.1016/j.amjcard.2006.07.079. Epub 2006 Nov 16. Am J Cardiol. 2007. PMID: 17223409 Clinical Trial.
Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
May HT, Anderson JL, Pearson RR, Jensen JR, Horne BD, Lavasani F, Yannicelli HD, Muhlestein JB. May HT, et al. Among authors: muhlestein jb. Am J Cardiol. 2008 Feb 15;101(4):486-9. doi: 10.1016/j.amjcard.2007.09.095. Epub 2007 Dec 26. Am J Cardiol. 2008. PMID: 18312763 Clinical Trial.
Hypothyroidism as a risk factor for statin intolerance.
Robison CD, Bair TL, Horne BD, McCubrey RO, Lappe DL, Muhlestein JB, Anderson JL. Robison CD, et al. Among authors: muhlestein jb. J Clin Lipidol. 2014 Jul-Aug;8(4):401-7. doi: 10.1016/j.jacl.2014.05.005. Epub 2014 May 27. J Clin Lipidol. 2014. PMID: 25110221
Temporal changes in statin prescription and intensity at discharge and impact on outcomes in patients with newly diagnosed atherosclerotic cardiovascular disease-Real-world experience within a large integrated health care system: The IMPRES study.
Anderson JL, Knowlton KU, May HT, Bair TL, Armstrong SO, Lappé DL, Muhlestein JB. Anderson JL, et al. Among authors: muhlestein jb. J Clin Lipidol. 2018 Jul-Aug;12(4):1008-1018.e1. doi: 10.1016/j.jacl.2018.03.084. Epub 2018 Mar 30. J Clin Lipidol. 2018. PMID: 29703626
310 results